June 2, 2016
Incentive Stock Option Grant
Vancouver, B.C., June 2, 2016 – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) announces, that it has granted a total of 1,500,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.085 per share and will expire June 2, 2021. Following this grant of options, the Company has 5,700,000 stock options outstanding.



May 30, 2016
Incentive Stock Option Grant
Vancouver, B.C., May 30, 2016 – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) announces, that it has granted a total of 4,000,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.08 per share and will expire May 30, 2021. Following this grant of options, the Company has 4,925,000 stock options outstanding.


May 19, 2016
Tule Valley Lithium Exploration Program
Vancouver, B.C., May 19, 2016 – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) is pleased to announce that further to the news of April 26, 2016 The Company has begun its initial exploration plan of identifying anomalous zones and geological mapping, to determine the presence and composition of lithium.  Activities may include, brine auger samples, surface sampling on the top of the playa along with the surrounding exposed bedrock.  If the aquifer is accessible at shallow depths a fluid sample will be taken and analyzed.

Tule Valley Lithium Exploration Project is prospective for lithium.  The property is 4,800 acres and is located approximately 190km south west of Salt Lake City, Utah.  Access is by an all-weather road from Delta, Utah.  

Mineral activity in the area includes;
Redhill Resources’ Honey Comb Beryllium-Rubidium-Lithium-REE project, located 20km north of Tule Valley.  Redhill indicates initial surface sampling assays of 1500-1700ppm lithium from a rhyolite dome (September 30, 2011 NI43-101 report).

Materion Corporations’ Spor Mountain beryllium mine is situated 30km to the northeast of Tule Valley.  Both the Honey Comb and Spor Mt projects indicate that the volcanic rocks surrounding Tule Valley are lithium-rich, and may have therefore acted as a source of lithium for local brines.

The Sevier Lake property of Crystal Peak Minerals, 60km to the southeast of Tule Valley, is a brine-sourced potash, lithium and magnesium project.  Crystal Peak’s November 18, 2013 NI43-101 report states that lithium values in post-production brine solution (after potassium-sulphate extraction) ranges from 50 to 200mg/l lithium (0.005%  to 0.020% Li).  Crystal Peak is an evaporite basin similar to Tule Valley.

  • A combined analysis of geophysical, geochemical and geological data suggests the possibility of anomalous Li/Be/Rb/K values could be located in the brines of the Tule Valley playa
  • The Tule Valley playa merits further exploration, including geophysics and drilling to evaluate potential for a mass brine deposit.

Jag Bal, President of Umbral commented, "With Crystal Peak Minerals recently announcing that they intend to focus on evaluating the development of lithium on their Sevier Playa project, Umbral is eager to immediately begin exploration on our Tule Valley project.”

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisions of National Instrument 43-101.


May 10, 2016
Umbral acquires the Gerlach Nevada Lithium Brine Project
UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) is pleased to announce that, Umbral Energy Corp. has entered into a property purchase agreement with Zimtu Capital Corp. to acquire a 100-per-cent interest in the Gerlach Nevada Lithium Brine Project. The property is 1,780 acres and is located approximately 125km north east of Reno, Nevada.  Access is by an all-weather road from Gerlach, NV.
‍‍‍
The exploration target is strategically placed in an underexplored closed basin. The basin sits in an area structurally comparable to that of Clayton valley, being bounded by normal faults to the east and west of the property and surrounded by volcanics such as rhyolitic flows and tuffs.

The company plans to immediately execute an exploration program to determine the potential of a mass Lithium brine. The exploration program will consist of surface sampling, along with shallow aquifer fluid analysis.  The preliminary sampling with be followed by a high resolution geophysical program to better define potential drill targets.

The Gerlach Lithium Project is one of the closest Li brine projects to the construction of Tesla’s Giga Factory.  The Gelach property is located only 120km to the north, this would allow feasible transportation of lithium compounds.

The company can earn a 100% interest in both the previously acquired Tule Valley Project and the Gerlach Project by completing the following: issuing three million common shares upon regulatory approval, and paying cash considerations totalling $160,000 over the next two years. A 2% NSR royalty has also been granted to the vendors, which half (50%) of the NSR Royalty can be purchased by the company at any time for $1-million.  

Jag Bal, President of Umbral commented,” The acquisition of the Gerlach project has quickly moved Umbral into one of the hottest sectors in the resource and energy space. The company believes that due to growing world demand for lithium, the Gerlach project, located in Nevada near Tesla's Gigafactory, has the potential to deliver strong returns for our shareholders over the short and long term. We look forward to aggressively advancing work on both of our projects.”

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisions of National Instrument 43-101.

The Company is not proceeding with the Washington State property lease announced on February 5, 2016.


April 26, 2016
Umbral acquires the Tule Valley Lithium Exploration Project
UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) is pleased to announce that it has entered into property purchase agreement with Zimtu Capital Corp. (the “Vendor”) to acquire a 100% interest in the Tule Valley Project which is prospective for lithium.  The property is 4,800 acres and is located approximately 190km south west of Salt Lake City, Utah.  Access is by an all-weather road from Delta, Utah.

Mineral activity in the area includes Redhill Resources, 20km to the north | Honey Comb Beryllium-Rubidium, Lithium and REE project, taken from Redhill’s September 30, 2011 NI43-101 reports initial surface sampling report assays of 1500-1700ppm lithium; Crystal Peak Minerals, 60km to the south east | potash, lithium and magnesium project, taken from Crystal Peak’s November 18, 2013 NI43-101 lithium values in solution (Brine) ranging from 50-200mg/l lithium.  Crystal Peak is an evaporite basin similar to Tule Valley; and Materion Corporation | Spor Mountain, 30km to the north east | Beryllium Mine.

Tule Valley prospect is similar to that of Clayton Valley, Nevada, as they are both closed basin and have similar horst and graben structures. The Tule Valley project requires further exploration, including geophysics and drilling to evaluate potential for a mass brine deposit.

A three stage exploration plan is being considered for the project, which may include:

  1. Soil/surface sampling, shallow groundwater fluid analysis
  2. High resolution gravity survey of the Tule Basin
  3. Data Compilation to allocate drill targets

The company can earn a 100% interest in the Tule Valley Project by completing the following, issuing three million common shares upon regulatory approval, and paying cash considerations totalling $160,000 over the next two years. A 2% NSR royalty has also been granted to the vendors, which half (50%) of the NSR Royalty can be purchased by the company at any time for $1-million.

Jag Bal, President of Umbral commented, "as demand for lithium rises, particularly with the production of electric vehicles and the energy storage movement, supply concerns have provided an opportunity which Umbral can participate in.  Lithium has gone from a steady, but relatively obscure commodity to being in extremely high demand  this year. For an example of this rising demand, one only needs to point to Tesla’s new battery gigafactory, which will need 15,000 tons of lithium carbonate a year just to get started.”

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisions of National Instrument 43-101.


April 18, 2016
Incentive Stock Option Grant
UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) announces, that it has granted a total of 2,500,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.05 per share and will expire April 18, 2021. Following this grant of options, the Company has 4,950,000 stock options outstanding.


February 5, 2016
Negotiating on a property for an I-502 compliant turn-key facility
UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) announces that Umbral Energy, LLC (State of Washington, limited liability company formed August 25, 2015), has entered into negotiations with a private Washington State company to lease with an option to purchase a commercially zoned 2.75 acre property, including a 2,528 square feet indoor space.  The property has 3 phase power and sufficient water for the establishment of a turn-key indoor growing / processing operation.

The Licence Applicant has requested that the indoor space be fitted with an Extraction Unit, which will allow for the License Applicant to extract cannabis concentrates (oils & edibles).  In addition the building will be purpose built to allow for year round growing, providing the required control of medicinal plants.  In addition the property has sufficient space to add 3 greenhouses.

Jag Bal, President of Umbral commented, “with Umbral receiving positive feedback from our partner,  PhyeinMed, on the status of our Health Canada MMPR Application and the commencement of negotiations for the lease with option to purchase a commercially zoned property, that will allow for the construction of a turnkey operation for a tier 3 I-502 license holder, the company is moving towards becoming a significant player in the rapidly expanding marijuana sector in both Canada and the United States.”

The Company is also evaluating additional opportunities throughout the United States where legislation has legalized marijuana for recreational use to leverage its business experience.”

The Company is not proceeding with the property announced on November 2nd, 2015.


February 2, 2016
Update on Medical Marijuana Application | Health Canada
UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) is pleased to announce, PhyeinMed Inc.’s application 10-MM0613 under Health Canada’s Marijuana for Medical Purposes Regulations is now at the personnel security checks stage.  

The application provides for the possession, sale, delivery, destruction and production of dried marijuana.  An option to purchase, upon an approval to complete our facility awaiting a pre-license inspection from Health Canada, has been completed.  The proposed growing site for growing medicinal marijuana is an 11,000 sq ft building within 13 acres of land.  The master security plan, architectural drawings, survey certificate and threat assessment report were completed for both the buildings, as well as, a complete site security plan for the property perimeter was submitted with the application.  The average values associated with a threat assessment score can be quite high and would increase any possible criminal threats to the facility, PhyeinMed’s threat assessment score was very low.

Jag Bal, President of Umbral commented, "“We are excited to be notified by our partner, Phyeinmed, that the application is progressing through the stages as set out by Health Canada, Phyeinmed has continued to work with Health Canada to complete and fulfill all of the necessary requirements prior to the security clearance phase of the application.  We have renewed confidence that the application process will continue through the required stages.”

News Releases

June 6, 2016

Tule Valley Lithium Exploration Program Update

Vancouver, B.C., UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF) (the “Company” or “Umbral”) is pleased to provide this update on the Tule Valley Lithium Exploration Project. The property is 4,800 acres and is located approximately 190km south west of Salt Lake City, Utah. Accessible by an all-weather road from Delta, Utah.

Reconnaissance Survey of the property consisted of:
a) Investigation of distribution of dry lake bed playa vs evaporite,
b) Testing/sampling local feeder-springs,
c) Wide-spaced “soil” sampling of the playa bed,
d) Informative meetings with local BLM personnel,

Tule Valley playa is a dry lake bed, mostly covered with a thin layer of wind-blown sand, with several active “evaporite ponds”, where leakage from near-by springs brings water onto the low-lying areas of the playa, thereby producing active evaporation. composed of dried mud/silt/ash, the compacted playa mud is salty (indicating some form of evaporation from either surface or ground waters during the life of the playa), and displays gypsum crystals (calcium sulphate; indicating the introduction of sulphate during the drying/evaporation process, which in turn suggests some form of groundwater influence). Tule Valley playa is a closed valley, has lithium source rocks located several kilometres north of the property, (see May 19, 2016 news release) has active groundwater flow along its western margin, and has been affected by evaporite-style processes. Tule Valley may therefore be conducive to the presence of lithium-bearing groundwater.

In this respect, Tule Valley has similar characteristics to Clayton Valley, Nevada, a dry lake bed where lithium is derived from brines located within more porous sediment layers at depth under playa. The Tule Valley exploration will focus initially on geophysical surveying, particularly IP, to detect conductive layers beneath the playa. Brines are salty, and are therefore strongly conductive. The thicker and strongest conductive zones will subsequently be drill-tested for lithium content.

Jag Bal, President of Umbral commented, “Our company is focused on evaluating the potential for development of lithium in Utah and Nevada. The lithium industry is growing very quickly, and Umbral is eager to be part of this. We strongly believe in the properties we have acquired, and we are looking forward to further exploration on our Tule Valley project.”

About Umbral Energy Corp.
The Company is currently listed as a junior resource issuer having mineral exploration projects. The Company is considering other activities to increase shareholder value, including non-resource projects.

The Company has a mineral exploration projects in Utah, Nevada and Quebec, as well as an interest in oil and gas property in Alberta. In addition the Company has an interest in PhyeinMed, who has applied for a license from Health Canada to legally grow and sell medical marijuana.

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisions of National Instrument 43-101.

Jag Bal, President & CEO

Umbral Energy Corp.

929 Mainland St.
Vancouver, BC V6B 1S3

604-628-1767

Home

Corporate

Projects

News

Investors

Contact Us

Umbral Energy Corp. is a resource exploration company, management will continue to review opportunities to increase shareholder value.

Copyright All Rights Reserved © 2016

Documents and information
click on the following link:
Documents filed on SEDAR‍‍‍

Share price information
click on the following link:  
CSE trading symbol | UMB

OTC trading symbol | UMBBF

ISSUED AND OUTSTANDING 79,991,972‍‍‍

June 23, 2016

San Emidio Property, Gerlach, NV, Exploration Program Update

Vancouver, B.C., UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) is pleased to provide an exploration program update on the Gerlach (San Emidio Desert) property, located near Gerlach, Washoe County, Nevada. The San Emidio Desert is the name given to the playa extending south from Gerlach. San Emidio is the southern “tongue” of the largest dry lake bed in North America (Black Rock Desert). The 89 claims cover an area of 1,780 acres, property is less than 3 miles from the town of Gerlach, NV.

The claim block is located within the southern lobe of the Black Rock Desert, a graben feature of the Basin and Range geological province which dominates throughout Nevada. San Emidio is a dry lake bed (playa), its edges covered with a thin veneer (up to 3m) of wind-blown sand dunes and mounds. In this respect, San Emidio is not a pure evaporite basin, such as Great Salt Lake, Sevier Lake, or the Bolivian and Chilean salars, where active evaporation and salt/phosphate-deposition (±Li) is on-going.

Although composed of dried mud/silt/ash, the compacted playa mud is salty (indicating some form of evaporation during the life of the playa). In this respect, the San Emidio playa may be more appropriately compared to Clayton Valley. Country rock along the eastern margin of the playa has been hydrothermally altered (eg, Empire Gypsum deposit, Wind Mountain epithermal Au/Ag deposit), suggesting high heat flow and intense groundwater flow. This activity would have leached lithium where present.

All well-known natural hot springs in the region occur to the north and NE of the town of Gerlach. These springs are located adjacent to the Black Rock Desert, and may feed its groundwaters, and those of the San Emidio basin. More important for UMB’s property is the presence of US Geothermals’ electro-generation plant located 27km south of the G01-89 claims on the E edge of the southern lobe of the San Emidio playa. This confirms the presence of geothermal activity (hence brines) in the San Emidio playa.

Nevada Energy Metals (TSX-V: BFF) states on their website that previous work on their San Emidio Lithium project has detected the presence of up to 312ppm Li (0.03%), averaging 250ppm, in the playa sediments (located in the southern lobe of the San Emidio playa, 26km south of UMB’s property, and adjacent to US Geothermals’ plant). Furthermore, they state that US Geothermal has reported “anomalous” Li content from brine samples at their facility.

The San Emidio playa appears to be a closed valley, may have lithium-bearing clays and/or ash in its sediments (see “xiv” above), has active, hot, Li-bearing groundwater flow along its eastern margin (US Geothermal, gypsum mine, etc), and has been affected by evaporite-style processes. The San Emidio property may therefore be conducive to the presence of lithium-bearing groundwater.

San Emidio exploration is expected to focus initially on geophysical surveying, particularly IP, to detect conductive layers beneath the playa floor. Brines are salty, and are therefore strongly conductive. The thicker and strongest conductive zones can subsequently be drill-tested for lithium content. Further research into the distribution of active hydrothermal activity along its eastern edge is also required.

Jag Bal, President of Umbral commented, “I am excited about the rapid progress Umbral has made on both the Tule and Gerlach Projects and look forward to continuing progress on both.Regarding Tule, initial samples collected have been sent to ALS Chemex in Elko, NV. and the company is awaiting results.

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisions of National Instrument 43-101.

July 22, 2016

Incentive Stock Option Grant

Vancouver, B.C., UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) announces, that it has granted a total of 550,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.05 per share and will expire July 22, 2021. Following this grant of options, the Company has 6,050,000 stock options outstanding.

August 4, 2016

Umbral Energy Samples Up To 204 PPM Lithium at Tule Valley Lithium Brine Project in Utah

Vancouver, B.C., UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) is pleased to announce that it has received geochemical results of up to 204 PPM Lithium fromsamples taken on its 100% owned Tule Valley Lithium Exploration Project.The property is 4,800 acres and is located approximately 190km south west of Salt Lake City, Utah.

A total of 4 water samples and 13 soil samples were collected from the property.The soils were crushed, pulverized and assayed for lithium and a suite of pathfinder elements (eg, K, Mg, B, F, Na, Ca, Li/K and Li/Mg ratios). Most soil samples were collected at the claim post sites that were located on exposed playa.

Samples of actively evaporating briny surface muds are all anomalous in lithium (>0.01% Li). Each of these anomalous samples (indicated in green) is very wet, saturated with salty brine, contains salt and/or gypsum crystals, and lies below 1340m altitude. These locations are where the playa surface dips below the current groundwater table (<1339m), wherein near-surface brines reach the surface, form shallow pools (<0.3m deep), and evaporate. The western half of the playa seems to lie at a lower altitude than the eastern half. The fact that both the surface brines (W03, 04) and resultant saturated muds are anomalous in lithium is deemed encouraging for the deposition of near-surface lithium mineralization on the property.

Samples of actively evaporating briny surface muds are all anomalous in lithium (>0.01% Li). Each of these anomalous samples (indicated in green) is very wet, saturated with salty brine, contains salt and/or gypsum crystals, and lies below 1340m altitude. These locations are where the playa surface dips below the current groundwater table (<1339m), wherein near-surface brines reach the surface, form shallow pools (<0.3m deep), and evaporate.The western half of the playa seems to lie at a lower altitude than the eastern half. The fact that both the surface brines (W03, 04) and resultant saturated muds are anomalous in lithium is deemed encouraging for the deposition of near-surface lithium mineralization on the property.

Jag Bal, President of Umbral commented,”`we are encouraged with our first round of exploration on our Tule Property. With the presence of Lithium as high as 204 ppm in our samples, we are now focused on phase two of our exploration program.”

Tule Valley has similar characteristics to Clayton Valley, Nevada, a dry lake bed where lithium is derived from brines located within more porous sediment layers at depth under playa. The Tule Valley exploration will focus initially on geophysical surveying, particularly IP, to detect conductive layers beneath the playa. Brines are salty, and are therefore strongly conductive. The thicker and strongest conductive zones will subsequently be drill-tested for lithium content.

Qualified Person:
The technical content of this news release has been reviewed and approved by Phil van Angeren, a registered Professional Geologist with APEGA, and a Qualified Person under the provisi‍‍‍ons of National Instrument 43-101.

October 5, 2016

Incentive Stock Option Grant

Vancouver, B.C., – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) announces, that it has granted a total of 750,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.05 per share and will expire October 5, 2021. Following this grant of options, the Company has 6,250,000 stock options outstanding.

October 12, 2016

Update on Medical Marijuana Application

Vancouver, BC – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) is pleased to provide an update on its 50% owned PhyeinMed Inc. (“PhyeinMed”), an operating company with a submitted application to Health Canada for a MMPR Licence.  

PhyeinMed Inc, is currently in Stage 4, Initiation of security clearance process, in Health Canada’s application of becoming a licensed grower under the Marihuana of Medical Purposes Regulations.PhyeinMed, its officers and directorshave submitted a security clearance application as required to Health Canada and are awaiting further feedback.

Jag Bal, President of Umbral states, “Umbral remains committed to the Health Canada process with our partner PhyeinMed, as they continue to work diligently through the various stages of the MMPR application process. We believe that PhyeinMed`s experienced team and their designated 13 acre site with an 11,000 sq. ft. building, which is located in Falkland, BC, has Umbral well positioned in this rapidly growing Cannabis sector in Canada. We have remained hopeful throughout this licensing process”.

November 24, 2016

Incentive Stock Option Grant

Vancouver, B.C., - UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) announces, that it has granted a total of 830,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.05 per share and will expire November 24, 2021. Following this grant of options, the Company has 6,330,000 stock options outstanding.

November 28, 2016

UMBRAL INDUSTRIAL HEMP APPLICATION

Vancouver, B.C., – UMBRAL ENERGY CORP. (CSE: UMB) (OTCQB: UMBBF)(the “Company” or “Umbral”) is pleased to announce that in partnership with a hemp based Canadian company is proceeding with an investment to finance the application of an industrial hemp licence.

On November 21, 2016, Health Canada issued a Section 56 Class Exemption in Relation to the Industrial Hemp Regulations (Exemption). The Exemption better aligns regulation of industrial hemp with the demonstrated low public health and safety risk of the crop. The Exemption is an interim measure to simplify the license application process as the Government moves forward with its commitment to legalize, strictly regulate, and restrict access to marijuana. Umbral plans to finance and participate in an industrial hemp license application for the purpose of cultivating hemp. Initially the partnership plans to take advantage of land currently under option and will identify the planting site within 15 days of seeding. Due to the regulation amendments there is no longer a minimum acreage requirement. One license will cover all cultivation sites and activities. The decision by Umbral and its partners to pursue this opportunity is based on the Government’s commitment to legalize cannabis and the opportunities to process hemp for a variety of ancillary industries.

According to the Canadian Hemp Trade Alliance (CHTA). "Hemp could serve as a Canadian medicinal health product because it contains cannabidiol (CBD) but almost no THC, the psychoactive component," says Kim Shukla, Executive Director, CHTA. "Ironically, today Canadians who need the beneficial cannabinoids to treat medical conditions only have recourse to marijuana, while these components of our hemp crops are being left to waste in Canadian fields. Hemp farmers want the option to harvest their entire crop and explore the opportunity for the whole plant, including cannabinoids such as cannabidiol (CBD)," adds Shukla. "New research continues to build the mounting body of evidence that CBD can have positive health effects, the situation is particularly poignant in the case of childhood epilepsy, for which high CBD is proving to be an effective treatment”.

There is a growing body of clinical research demonstrating its potential therapeutic uses. Many natural health products including topical formulations could be developed. There are high levels of CBD in hemp and hemp does not have the psycho-activity that is prevalent in cannabis. Right now, the cost to patients of high CBD cannabis is equivalent to high THC cannabis as it is being grown in the same high security facilities. Allowing hemp farmers to harvest CBD from their crops could substantially reduce the cost of CBD for patient care.

November 30, 2016

ACMPR APPLICATION UPDATE

Vancouver, B.C. – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) is pleased to announce that PhyeinMed Inc. (“PhyeinMed”) is in communication with Health Canada and its ACMPR (Access to Cannabis for Medical Purposes Regulations) application has been assured that the application is progressing through the application process.

PhyeinMed’s President & CEO Debra Senger states “We have been satisfied with the progress of the application these last few months. Health Canada is finalizing the final vetting process from the information they receive from various government departments responsible for security clearances with respect to PhyeinMed’s corporate personnel and persons in charge of the application. Although the time restraints involved with the application have been lengthy, we have been able to continue with the process and maintain confidence with our partners and key persons involved in the application. We look forward to progressing to the final review stage and await the approvals necessary to receive a prepare for inspection notification from Health Canada. Once received, PhyeinMed plans to proceed with the acquisition of its facility and prepare for inspection.”

The Liberal government has emphasized their desire to legalize, regulate, and restrict access to cannabis and the move towards legalization in 2017 is likely to start with government-vetted Licensed Producers as suppliers. Estimates in the Canadian cannabis space could reach $3.0B in annual sales in 2024 with an even larger recreational market of $3.0B - $5.0B that same year, for a combined total of $6.0B - $8.0B, with further upside coming from increased tourism and international expansion or trade. Based on a recent published report 1,749,790 square meters of indoor grow space will be required to supply the Canadian recreational market or over 290 CFL football fields.PhyeinMed’s total potential new grow area with expansion could be 420,000 square feet of grow space using an additional seven acres of the land included in the current proposed property acquisition.

The management of PhyeinMed has been nurturing potential partnerships, international export and import partners, strategic alliances, accessory and ancillary relationships, revenue generating opportunities during the course of theapplication process. Short term and long term goals for creating revenue have been identified and the company plans to investigate and pursue these opportunities moving forward with Umbral as an investment partner.

December 14, 2016

Cannabis Task Force Report Implications

Vancouver, B.C. - UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) with its partner, PhyeinMed Inc. (“PhyeinMed”) is encouraged by the recommendations releasedby the Canadian government's task force report on marijuana legalization and regulation. The Liberal government has emphasized their desire to legalize, regulate, and restrict access to cannabis and the Task Force was engaged to complete the task of compiling recommendations which included government-vetted Licensed Producers as suppliers.

PhyeinMed is an ACMPR (Access to Cannabis for Medical Purposes Regulations)applicant to become a licensed producer and believes that the recommendations put forth by the task force have a direct and encouraging impact on the direction of the company’s business plan moving forward.

Debra Senger, Chief executive officer of PhyeinMed,commented: “We are encouraged by the recently released recommendations of the Canadian government's task force on marijuana legalization and regulation.With the extent of information submitted and gathered, I believe that the Government will adopt a sizeable number of the 80 or so outlined in the report. The Government would still need to draft legislationwhich is likely going to be spring 2017 with the intent to publish the revised legislation in the fall of next year at which time the new legislation will become law. While watching the press conference televised yesterday morning it was very apparent that both the Chair and Co-Chair of the task force agreed that the supply and demand under the new legalized recreational cannabis program would be significant. My belief, if a company is currently in the queue to become a producer such as ourselves of medical marijuana under the ACMPR, that we are preparing for the legal marketand a license for production.The system has been slow, which has discouraged many applicants. However, with the new legal market coming to Canada, the task force has absolutely acknowledged that supply will need to be ramped up and quickly.In the report “Canada’s governments will need to move swiftly to increase or create capacity in many areas relating to the production and sale of cannabis”. We are currently in the security clearance stage and I am hopeful that we will move into the next stage of the application early in the new year.”

PhyeinMed with its investment partner Umbral, will continue with short and long term initiatives to investigate and pursue ancillary opportunities in the cannabis industry.

January 13, 2017

RISKS AND UNCERTAINTIES INHERENT TO THE PROPOSED MEDICAL MARIJUANA BUSINESS

Vancouver, B.C., January 13, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) with its partner, PhyeinMed Inc. (“PhyeinMed”) is issuing this press release as a result of a review by the British Columbia Securities Commission (the “BCSC”). This clarifying news release is intended to provide further disclosure about the Company’s pursuit of opportunities in the medical marijuana business.

Principal Business

The Company plans to continue its principal business of mineral exploration. The Company’s pursuit of medical marijuana business is supplementary to the mineral exploration business. Theboard of directors have approved the Company’s entry into the medical marijuana business and to the Company’s knowledge, this is the only approval required for the Company’s pursuit of opportunities in the medical marijuana business.

Information About the ACMPR Licensing Process

The Company through its partner, PhyeinMed Inc., has applied for to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations. The licensing process to apply for the access to cannabis for medical purposes regulations (the “ACMPR”) involves a strict and thorough review. There are many stages to the application process for becoming a licensed producer of cannabis for medical purposes as described below:

(a) Applications Received;

(b) Preliminary Screening;+

c) Enhanced Screening ;

(d) Initiation of Security Clearance Process;

(e) Review;

(f) Pre-licence Inspection; and

(g)Licensing.

An applicant may be sent back to a stage previously cleared if new information affecting the application is received by Health Canada. Also, an application can be refused at any stage of the process.

Preliminary Screening

When an application is received, it undergoes a preliminary screening for completeness. If an application is not complete, it will be returned. If an application appears to be complete, it will be assigned an application number. The application number means that the application has completed the preliminary screening. Applicants should reference their application number in all correspondence with Health Canada.

Enhanced Screening

Once an application has been assigned an application number, it will be reviewed to ensure that the level of detail included in the application is sufficient to assess the requirements of the regulations. Initial consideration is also given to the location of the proposed site; likely risks to public health, safety and security; the proposed security measures; and the credentials of the proposed quality assurance person to meet the good production requirements outlined in Subdivision D of the ACMPR. On a case-by-case basis Health Canada may also request and/or review other information that is relevant to the application. Health Canada will also verify that applicants have provided notice to the senior official with the local government where their proposed site is located. Licensed producers are required to comply with all applicable provincial/territorial and municipal laws, including zoning restrictions, fire and electrical safety, and waste management.

Security Clearance

Once the screening of an application is complete, the security clearance forms for key personnel will be sent for processing. When applying for a licence to produce under the ACMPR, a Security Clearance Application Form must be submitted for the following individuals:

·the proposed senior person in charge;

·the proposed responsible person in charge;

·the proposed alternate responsible person(s) in charge (if applicable);

·if a producer's licence is issued to an individual, that individual; and

·if a producer's licence is issued to a corporation, each officer and director of the corporation.

Review

An application will be thoroughly reviewed to validate the information provided. Given the extensive review process, applicants should anticipate communicating with the Office of Medical Cannabis multiple times to provide clarifications on the application. Health Canada may also request additional information from the applicant as required. Physical security plans will be reviewed and assessed in detail at this stage. Please note that applicants must comply with the Directive on Physical Security Requirements for Controlled Substances. When Health Canada believes an application is ready for a pre-licence inspection, Health Canada will contact the applicant and identify the information that needs to be confirmed before a pre-licence inspection can be scheduled.

Pre-Licence Inspection

Section 21 of the ACMPR (Inspection of Site) allows for the possibility of a pre-licence inspection. This includes, but is not limited to: security measures, good production practices, packaging, labelling and shipping, registration, and record keeping.

Licensing

The results of the pre-licence inspection are reviewed with all the information submitted to Health Canada, and any other relevant information, to complete the assessment of the application in keeping with the requirements of the ACMPR, establish that the issuance of the licence is not likely to create risks to public health, safety or security, including the risk of cannabis being diverted to an illicit market or use, and there are no other grounds for refusing the application. The process for the initial issuance of a licence includes limits on licensed activities and a maximum limit on the total amount of cannabis authorized for production.

Application processing times are variable and depend on a number of factors, including:

·the completeness of the application and the thoroughness of the information provided;

·the timeliness of applicant responses to requests for additional information;

·the readiness of the applicant to move through the process;

·the complexity of the application; and

·whether the application poses any risks, including a risk to public health, safety or security.

The timeline for security screening of key personnel can also vary depending on the complexity of the applicant's file. The entire application process can take more than a year to complete. It is the responsibility of the applicant to ensure that the information provided in their application is detailed and accurate and clearly demonstrates that they are compliant with all the requirements of the ACMPR. Insufficient or inaccurate information may give rise to grounds for refusal.

Licences are only issued once all regulatory requirements are met. Each application undergoes a detailed assessment, including in-depth security checks led by the RCMP and site inspections. Health Canada conducts compliance and monitoring activities of regulated parties to ensure compliance with the various regulations to the Controlled Drugs and Substances Act (CDSA). These activities include education, complaint investigations and inspecting licensed sites, or sites applying to be licensed to conduct regulated activities. Licenses are only valid for one year and are subject to renewal approval by continuing to meet the requirements of the Access to Cannabis for Medical Purposes Regulations (ACMPR) including, but not limited to:

·Physical Security Measures;

·Good Production Practices;

·Packaging, Labelling and Shipping Requirements;

·Import and Export permit, if applicable; and

·Security Clearance.

Physical Security Measures

Production, packaging, labelling and storage activities under the ACMPR need to be conducted indoors, and not in a dwelling place. The ACMPR set out physical security requirements that are necessary to secure sites where licensed producers conduct activities with cannabis other than storage. For storage of cannabis, other than marijuana plants, Health Canada's Directive on Physical Security Requirements for Controlled Substances establishes security requirements for the storage of all controlled substances including cannabis by licensed producers. All applicants for a producer's licence have to demonstrate to Health Canada that they meet these security requirements. Licensed producer sites are subject to compliance and enforcement measures, including regular audits and inspections by Health Canada.

Good Production Practices

Licensed producers are subject to Good Production Practices that are meant, among other things, to ensure the cleanliness of the premises and equipment. The licensed producer is required to employ a quality assurance person with appropriate training, experience, and technical knowledge to approve the quality of fresh and dried marijuana, marijuana plants and seeds, and cannabis oil prior to making it available for sale.

Product Quality

Licensed producers must conduct tests on their products, including, as applicable:

·for microbial and chemical contaminants of fresh and dried marijuana, and cannabis oil

·for disintegration of capsules or similar dosage forms of cannabis oil; and

·for residues of solvents in cannabis oil for content of delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabinolic acid, cannabidiol and cannabidiolic acid.

Other requirements

Licensed producers must also meet other requirements under Good Production Practices under the ACMPR including, but not limited to:

·Sanitation Program;

·Standard Operating Procedures; and

·Establishment of a Recall System.

Packaging, Labelling and Shipping – Consumer Information

The ACMPR sets out requirements for packaging, labelling and shipping. For example, fresh and dried marijuana, cannabis oil, and marijuana seeds and plants must be sold or provided in tamper-evident containers or packages. Fresh and dried marijuana and cannabis oil must be sold or provided in child-resistant containers. Separate labelling requirements apply depending on the product type (i.e. fresh and dried marijuana, cannabis oil, cannabis oil in capsule or similar dosage forms, and marijuana plants and seeds). In addition, all licensed producers are required to attach a client-specific label, similar to a patient-specific prescription drug label, to the container, package or plant. Under the ACMPR, each shipment sold to a client needs to be accompanied by a copy of the most current version of the Health Canada document entitled “Consumer Information - Cannabis (Marihuana, marijuana)”. This document provides a summary of the known information about the uses and risks of cannabis for medical purposes so that individuals can be informed about their treatment choice.

Import and Export Permit

A licensed producer must obtain a permit from the Minister of Health prior to importing or exporting marijuana or cannabis for the purpose of testing cannabinoid content.

Information Concerning PhyeinMed’s Application

PhyeinMed submitted the application under the ACMPR on December 9, 2014. Preliminary screening was concluded and an application number was assigned to PhyeinMed under the ACMPR. Enhanced Screening and many subsequent requests for additional information were completed satisfactorily. PhyeinMed was notified by the offices of medical cannabis within Health Canada on January 22, 2016, that the Security Clearance stage of the application process was being initiated. To date the business plan to produce medical cannabis is to wait for the application process to move to final review stage. No further business is required until PhyeinMed receives notification of final review. At that time several initiatives should be undertaken, completion of the business plan in relation to the current regulations, if this includes adult use or recreational use of cannabis, branding within the guidelines of the recreational market, plans to complete the purchase of the property, site and property preparation to prepare for estimates and any and all other preliminary work that can be completed prior to the pre-license inspection notification.

PhyeinMed’s key persons in conjunction with its Quality Assurance Person and various professional consultants in the cannabis industry completed the application and believe it has met the regulatory requirements as outlined in the guidance documents provided by Health Canada. Under the guidance of the Quality Assurance Person; Good Production Practices were established under the ACMPR. Architectural drawings and a Site Survey Plan were commissioned. These plans were necessary to complete the security measures such as physical barriers, visual monitoring and recording devices as outlined in the Master Security Plan and Threat Assessment Report submitted for the location. PhyeinMed to the best of its knowledge has met the minimum of a level 7 (as defined in the Directive on Physical Security Requirements for Controlled Substances (Licensed Dealers Security Requirements for the Storage of Controlled Substances) to be considered for a licence.

A time or cost estimate cannot be provided as PhyeinMed’s application is in the preliminary stage.Health Canada would not approve, grant or authorize any license to PhyeinMed prior to the construction of the facility and subsequent pre-licence inspection.

PhyeinMed does not currently own the property, the current property owners have consented to the use of the site by the applicant for the proposed activities as required in the application form. Upon notification from Health Canada to prepare for a pre-license inspection, PhyeinMed plans to purchase the property. Construction, installations and site preparation would commence on the property and the existing structures to meet the strict ACMPR as outlined in the application and completed prior to inspection. The process for the initial issuance of a licence includes limits on licensed activities and a maximum limit on the total amount of cannabis authorized for production. This is usually referred to as a license to cultivate.Once and if PhyeinMed has met the ACMPR of the initial license the company could be approved to become an Authorized Licensed Producer permitted to sell or import/ export cannabis. The process to become an authorized licensed producer can be well over a year.

About Umbral Energy Corp.

The Company is currently listed as a junior resource issuer having mineral exploration projects. The Company is considering other activities to increase shareholder value, including non-resource projects.

The Company has mineral exploration projects in Utah, Nevada and Quebec. In addition the Company has an interest in PhyeinMed, who has applied for a license from Health Canada to legally grow and sell medical marijuana.

February 10, 2017

UNAWARE OF ANY MATERIAL CHANGE

Vancouver, B.C., February 10, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) at the request of IIROC, the Company wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

February 10, 2017

INCENTIVE STOCK OPTION GRANT

Vancouver, B.C., February 10, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) announces, that it has granted a total of 3,450,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.07 per share and will expire February 10, 2022. Following this grant of options, the Company has 6,400,000 stock options outstanding.

February 16, 2016

UMBRAL'S PARTNER PHYEINMED RECEIVES ACMPR APPROVAL TO COMMENCE STAGE 5

Vancouver, B.C., UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral” or “Company”) is pleased to announce that PhyeinMed Inc. (“PhyeinMed”) has received notification from Health Canada that its ACMPR (Access to Cannabis for Medical Purposes Regulations) application has progressed through to the Review Stage (stage 5 of 7) of the application process.

“Having the application successfully move to the Review Stage is a monumental step for Umbral and our partner PhyeinMed.  The goal of becoming a licensed producer in Canada has moved closer to becoming a reality” states Jag Bal, president and CEO of Umbral Energy Corp.

All of the key persons submitted with the application have undergone a rigorous and thorough screening process and have been approved. The checks conducted go beyond the verification of an individual's criminal record check and include a check of the relevant files of law enforcement agencies, including intelligence gathered for law enforcement purposes.

PhyeinMed Inc., owned 50% by Umbral is committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations ("ACMPR").  PhyeinMed’s property located in Falkland BC, is 13 acres of potential grow area with a 10,000 sq. ft. steel framed building.  PhyeinMed will initiate an aggressive growth strategy, planning an additional 20,000 sq. ft. phase II production facility expansion on the current site.  Future expansion utilizing 100% of the land use capabilities could allow for a total of 420,000 sq. ft. of growing capability.  Having the ability to expand at one site affords Phyeinmed redundancy and the ability to increase productivity without the need to duplicate personnel in key roles.

PhyeinMed’s CEO, Debra Senger states “We are very happy with the recent news of our application status. As with most active applicants, the process can be grueling.  I am thankful for the team of professionals that supported this process and the loyal shareholders of Umbral who continued to believe in our application.  I believe one of the more difficult hurdles of the application process is behind us.”

February 17, 2017

Umbral assigns interest in Tule Valley, Utah and Gerlach, NV Lithium Projects

Vancouver, B.C., February 17, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral” or “Company”) is pleased to announce that subject to regulatory acceptance, Umbral has entered into an Assignment Agreement with Equitorial Exploration Corp. for them to acquire 100% interest in the Tule Valley project in Utah and the San Emidio Project in Gerlach, NV.

As per the agreement and subject to regulatory approval, Equitorial shall pay Umbral the sum of $50,000 on execution of this agreement and shall issue to the Umbral 2,000,000 common shares upon regulatory acceptance.  In consideration for the assignment of the underlying agreement, Equitorial will assume a final payment of $100,000 to the underlying owner and Umbral will issue 1,500,000 shares for 100% interest in the properties.  There is a 2% NSR in favour of the underlying owner.

February 21, 2017

UMBRAL INITIATES FALKLAND, BC PROPERTY PURCHASE AND PREPARES FOR ACMPR FACILITY RETROFIT

Vancouver, B.C., February 21, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) is pleased to announce that it has initiated the purchase of the property located in Falkland, BC. to be used to grow medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and its 50% interest in an application submitted by PhyeinMed Inc. (“PhyeinMed”). PhyeinMed is a Stage 5 Review applicant owned 50 % by Umbral.

The property is a combination of 13 acres of useable development, a 10,000 sq. ft. commercial steel framed building and a residence to be used for executive offices, call centre, accounting and security screening.  The medical cannabis grow facility is a short commute from several city centres in the region, allowing for ease of accessibility to labour and shipping requirements.

The purchase of the property and the completion of final renovation design and engineering has been initiated and expected to be completed within 90 days.  Due to the existence of the current buildings, new structures are not required for the initial phase but a small expansion of one building will be required to accommodate the security measures required for the shipping vestibule.  Notifications were sent to the local official departments which included the RCMP, fire department and Columbia Shuswap Regional District as required under the ACMPR.  Upon notification to prepare for a pre-license inspection has been received by PhyeinMed from Health Canada, the facility will be well positioned with most if not all of the renovation and security requirements completed.

PhyeinMed anticipates that Health Canada will request additional information to confirm that the proposed site and storage security measures are in place, functional and comply with the requirements of the ACMPR and the Directive on Physical Security Requirements for Controlled Substances.  In anticipation of the security requirements the Company completed and submitted with its original application thorough standard operating procedures, a master security plan, threat assessment report, vault requirements, site survey plan and architectural drawings to complete the necessary overlays for the security equipment to meet the requirements.   Upon completion of the necessary requests and confirmation that the measures are in place Phyeinmed expects an affirmation letter from Health Canada.

Although PhyeinMed’s property is 13 acres of potential grow area, the company chooses to utilize the original building of 10,000 sq ft.  Perfecting the growing process and utilizing the most technologically advanced systems while maintaining the integrity of the plant and adhering to public health safety are of the utmost importance to the management of PhyeinMed.  Future plans utilizing 100% of the land use capabilities could allow for several additional expansion opportunities.

February 27, 2017

INCENTIVE STOCK OPTION GRANT

Vancouver, B.C., February 27, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) announces, that it has granted a total of 6,000,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.065 per share and will expire February 27, 2022. Following this grant of options, the Company has 6,900,000 stock options outstanding.

March 6, 2017

UMBRAL ACQUIRES ADDITIONAL 25% INTEREST IN PHYEINMED, A HEALTH CANADA ACMPR STAGE 5 REVIEW STAGE APPLICANT

Vancouver, B.C., March 6, 2017 – UMBRAL ENERGY CORP. (CSE: UMB)(OTC: UMBBF) (“Umbral or Company”) is pleased to announce that it has signed a binding Letter of Intent (“LOI”) to acquire an additional 25% interest in PhyeinMed Inc. (“PhyeinMed”), a Health Canada Stage 5 Review Stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations).  With this purchase, Umbral now holds 75% ownership of PhyeinMed Inc.

Jag Bal, president and CEO states“ Umbral has quickly positioned itself as the majority owner of an exceptional company in PhyeinMed.  We are eager to assist PhyeinMed in their mission of becoming a licensed producer in Canada”

Currently PhyeinMed is owned 50% by Estek Ventures Corp. (Estek).  This agreement will see Umbral acquire an additional 25% via its wholly owned subsidiary 1005477 BC Inc.  The revised ownership of PhyeinMed will be Umbral with 75%, and Estek with 25%.

The Terms of the agreement are as follows:

$100,000.00 CAN cash payment

  • $50,000.00 due on signing of the LOI (paid)
  • $50,000.00 due on completion of Share Purchase Agreement

7,000,000 shares in Umbral Energy Corp (C:UMB) | Released over 3 year escrow period

  • 100% of all shares released from escrow upon ACMPR Stage 7 license approval awarded if this is accomplished prior to the 36 months
  • 100% of all shares released from escrow as of 36 months if not released prior.

Estek to be granted a bonus of 1,000,000 shares of Umbral Energy Corp. (C:UMB) upon final award of ACMPR Stage 7 license approval awarded, no escrow on this award.

Pre-build preparations have started and PhyeinMed has started the preliminary work required to complete the renovations and security requirements for the 13 acre property with a 10,000 square feet steel framed building in Falkland, British Columbia.  Once an affirmation letter has been received from Health Canada, PhyeinMed will be prepared for an inspection.

PhyeinMed’s CEO Debra Senger and owner of Estek Ventures Corp states “I am very pleased with the recent developments, I believe we as a team, Umbral and myself, having an interest in the public company will be far more committed to the direction of the company as one cohesive unit. I look forward to our journey and I am excited for the future”

The company also plans to build through potential partnerships, international opportunities, strategic alliances, accessory and ancillary relationships with an emphasis on future revenue generating cannabis opportunities.

March 27, 2017

UMBRAL APPLAUDS UPCOMING CANNABIS LEGALIZATION ANNOUNCEMENT

Vancouver, B.C., March 27, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) and the management of PhyeinMed Inc. (“PhyeinMed”) a Health Canada Stage 5 (Review Stage) applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) are pleased with the continued progress of our application due to the recent CBC news report released March 26, 2017 relating to the legalization of cannabis for non medical use. Umbral recently acquired an additional 25% interest in PhyeinMed Inc., and now holds a total of 75% of the total equity.

Quoting from the article “CBC News has learned that the legislation will be announced during the week of April 10 and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan.

Bill Blair, the former Toronto police chief who has been stickhandling the marijuana file for the government, briefed the Liberal caucus on the roll-out plan and the legislation during caucus meetings this weekend.

The federal government will be in charge of making sure the country's marijuana supply is safe and secure and Ottawa will license producers.  While Ottawa will set a minimum age of 18 to buy marijuana, the provinces will have the option of setting a higher age limit if they wish.  The Liberals had promised to introduce legislation by the Spring of 2017. Announcing the legislation the week of April 10 will allow the party to hit that deadline.

PhyeinMed’s CEO Debra Senger  “I am pleasantly surprised with the recent news report published by the CBC, we had prepared ourselves for spring 2019 legalization, this is good news for our project as we will be ready for a robust recreational market next spring.”

The company will continue to build shareholder vue conducting due diligence on potential partnerships, international export opportunities, strategic alliances, accessory and ancillary both medical and non medical markets and services that will be in demand upon cannabis legalization.

Umbral assigns interest in Tule Valley, Utah and Gerlach, NV Lithium Projects

Vancouver, B.C., April 7, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral” or “Company”) is pleased to announce that further to the news release of February 17, 2017, the Company has assigned its 100% interest in the Tule Valley, Utah and the Gerlach, Nevada lithium brine properties.

Equitorial Exploration Corp. (“Equitorial”) has acquired 100% interest in the Tule Valley project in Utah and the San Emidio Project in Gerlach, NV.As consideration, the Company has been issued 2,000,000 common shares in the capital of Equitorial, which are subject to a statutory hold period ending August 8, 2017 in accordance with applicable securities legislation, at an issue price of $0.075 per Share, Equitorial has paid cash consideration to the Company in the amount of $50,000.Equitorial has assumed a payment of $100,000 and Umbral will issue 1,500,000 shares in favour of the underlying owner of the registered owner.There is a 2% NSR in favour of the underlying owner.

UMBRAL COMPLETES OFFER TO PURCHASE PROPERTY

Vancouver, B.C., May 10, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) and the management of PhyeinMed Inc. (“PhyeinMed”) a Health Canada Stage 5 applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) are pleased to announce the completion and acceptance of the offer to purchase the property in Falkland, BC for the purposes of cannabis production.

The purchase price for 13 acres of land, the current structures including 10,500 sq ft of potential grow area and a stand alone administration building is $995,000. The terms of the offer to purchase the property is the payment of a partial deposit of $25,000 (paid) upon acceptance of the offer, the balance of the deposit $75,000 to be paid upon subject removal, July 15, 2017. Possession of the property is September 29, 2017.

Pre build preparations are well underway and grow methodologies, equipment requirements and permits and inspections have been conducted. Due to the location of the property the ease to conduct these necessary requirements, for both application compliance and construction, has been an easy process.

PhyeinMed has engaged the services of an architectural firm and is awaiting confirmation of engineering quotes to complete the engagement for services.  PhyeinMed is pleased with the progress of the application and looks forward to completing the final requirements in Stage 5 of the application and notification to prepare for a pre-license inspection.

INCENTIVE STOCK OPTION GRANT

Vancouver, B.C., June 21, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) announces, that it has granted a total of 500,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan. The options are exercisable at $0.055 per share and will expire June 21, 2022. Following this grant of options, the Company has 3,050,000 stock options outstanding.

UMBRAL ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE ADDITIONAL 25% INTEREST IN LATE STAGE ACMPR APPLICANT PHYEINMED AND PROVIDES CORPORATE UPDATE

Vancouver, B.C., July 5, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) is pleased to announce that it has entered into a share purchase agreement dated effective June 21, 2017 (the “SPA”) among Umbral, its wholly-owned subsidiary 1005477 B.C. Ltd., Estek Ventures Corp. (the “Vendor”) and Debra Senger (“Senger”).Umbral and the Vendor currently each own 50% of the issued and outstanding common shares of PhyeinMed Inc. (PhyeinMed”), a late stage Health Canada Access to Cannabis for Medical Purposes Regulations (“ACMRP”) applicant for the purpose of growing, selling and distributing medical cannabis.Pursuant to the terms of the SPA, Umbral has agreed to acquire 50% of the Vendor’s holdings in PhyeinMed, representing 25% of PhyeinMed’s issued and outstanding share capital (the “Acquisition”), such that on closing of the Acquisition (the “Closing”), the resulting shareholdings in PhyeinMed will be 75% for Umbal and 25% for the Vendor.

Jag Bal, President and Chief Executive Officer, states: ”this definitive agreement is the completion of yet another milestone for Umbral as it continues to build tangible value for shareholders.Our meaningful forward progress, as well as recent changes announced by Health Canada for the marijuana industry, make us extremely excited about our future with PhyeinMed, and assisting them in becoming a licensed producer in Canada in the very near future.”

In consideration for the Acquisition, the Company has agreed to the following terms and conditions:

·The Company will pay a total of $120,000 ($50,000 of which has been paid, $50,000 of which will be paid on Closing and $20,000 of which will be paid upon completion by the Company of equity financing(s) that have raised gross proceeds of at least $1,500,000);

·The Company will issue 7,000,000 common shares in the capital of the Company (“Shares”) at Closing.Such shares will be subject to a four month hold period under applicable securities laws, and will be subject to a voluntary escrow period pursuant to which 10% of the Shares will be released on Closing and an additional 15% of the Shares will be released every six months thereafter;

·The Company will issue an additional 4,000,000 Shares upon final award of an ACMPR production license;

·The Company will grant 2,000,000 stock options to Senger to acquire up to 2,000,000 Shares at an exercise price no higher than $0.09 per Share;

·The Company will award to Senger 2,400,000 restricted stock units to Senger and an additional 1,600,000 RSU’s to eligible recipients; and

·The Company will commit up to an additional $3,000,000 to fund PhyeinMed’s efforts in the medical marijuana business (the “Loan”).

Completion of the Acquisition is subject to a number of conditions, including but not limited to, regulatory approval, including acceptance by the Canadian Securities Exchange (the “CSE”).

PhyeinMed's Chief Executive Officer, Debra Senger, and owner of Estek Ventures, states: "This transaction creates greater alignment between Umbral and Estek as we combine our efforts within PhyeinMed towards becoming a Licensed Producer of cannabis in Canada.The entire PhyeinMed team and I are very encouraged by the recent progress being made by Health Canada to streamline the licensing process to meet the expected high future demand.”

Umbral Business Update

The Company through its partner PhyeinMed has applied to become a licensed producer under the ACMRP.The licensing process involves a strict and thorough review.Effective May 25, 2017, Health Canada abridged and amended the application process for prospective licensed producers.There are many stages to the application process for becoming a licensed producer of cannabis for medical purposes as described below (for further information please visit Health Canada’s website at https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/application-process-becoming-licensed-producer.html):

  1. Intake and Initial Screening
  2. Detailed Review and Initiation of Security Clearance Process
  3. Issuance of Licence to Produce
  4. Introductory Inspection (as cultivation begins)
  5. Pre-Sales Inspection
  6. Issuance of Licence to Sell

The company has successfully completed the Security Clearance Process and is now in the Detailed Review stage.An applicant may be sent back to a stage previously cleared if new information affecting the application is received by Health Canada. Also, an application can be refused at any stage of the process.

At this time, the Company is being permitted to complete the Acquisition and to build out a grow facility, and upon completion, it is expected to receive permission from Health Canada to cultivate initial crops.Once the Company has completed a property acquisition for such facility and received further clarity from Health Canada, it intends to undertake a “change of business” transaction pursuant to CSE policies.

In addition, Umbral also plans to conduct a 2017 work program on its 100% owned Letourneur Gold Project in Quebec.Umbral is also in discussions with potential joint venture partners to further develop and explore the Letourneur Gold project.The Company expects to allocate up to $1,000,000 dollars for expenditures on the property.

As such, the Company currently remains a resource issuer and plans to continue its principal business of mineral exploration until it can gain better certainty surrounding the Health Canada licensing process.As there can be no guarantee that such milestones will be achieved and significant risks still exist in the application approval process, until such time, the Company will simultaneously pursue both medical marijuana and mineral exploration businesses.  

UMBRAL ACMPR APPLICANT PHYEINMED PREPARES TO EXPAND TO OVER 420,000 SQUARE FEET

Vancouver, B.C., July 6, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) and the management of PhyeinMed Inc. (“PhyeinMed”) a late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) are pleased to announce that planning and preparations have begun to build a 420,000 square foot cannabis production facility consisting of two buildings on 13 acres of land in Falkland, British Columbia.

On May 26, 2017 Health Canada released a bulletin updating the application stages, increasing production based on vault size and providing applicants the opportunity to expand current application sites with less regulation. Health Canada sent requests to applicants to identify their readiness to start construction, increase production and to identify expansion plans. These two events have allowed the company to immediately begin expansion preparations

The expansion plan includes two buildings and four phases of construction. The first phase is a building envelope of 130,000 sq ft.Second phase is the second level completion of equal square footage bringing the total of the first building to 260,000 sq ft. The second building, first floor phase three construction, is 80,000 sq ft. Fourth and final phase construction of the second level completes the 420,000 square foot expansion plans. Once the entire project is completed and licensed it has the potential to produce over 110,000 kg of cannabis per year or over $500 million annually.

The current facility is a 15,500 sq. ft. warehouse retrofit. With the recent events regarding changes allowed within the Health Canada application process the company is constructing a second level of the current warehouse increasing the grow capacity by an additional 5000 sq ft from the original application of 10,500 square feet. A state-of-the-art retrofit of the existing warehouse utilizing a hybrid hydroponic aeroponic grow method will increase annual production to 3700 kg of dry cannabis or over $25 million annually. Oil extraction will commence upon issuance of a production/sale license.

PhyeinMed is pleased with the recent regulation changes, updates and additional resources added to the application process and continues with construction plans of its current facility.

About Umbral Energy Corp.

The Company is currently listed as a junior resource issuer having mineral exploration projects. The Company is considering other activities to increase shareholder value, including non-resource projects.

The Company has a mineral exploration project in Quebec. In addition the Company has an interest in PhyeinMed, who has applied for a license from Health Canada to legally grow and sell medical marijuana.

UMBRAL COMPLETES THE SUBJECT REMOVAL FOR THE PURCHASE OF THE FALKLAND PROPERTY

Vancouver, B.C., July 13, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) and the management of PhyeinMed Inc. (“PhyeinMed”) a late stage applicant under the ACMP (Access to Cannabis for Medical Purposes Regulations) are pleased to announce it has paid the second instalment of $75,000 on its targeted acquisition in Falkland, BC, completing subject removals. This payment is in addition to the original $25,000 it paid on May 10, 2017 when it completed the Letter of Intent to purchase the property, leaving a balance to be paid of $895,000 on the original total purchase price. The full amount remaining is set to be completed on or before September 29, 2017.

The purpose of this acquisition is to allow PhyeinMed Inc., to complete the planned build-out as it continues to move towards achieving its goal of becoming a licensed producer.The property includes 13 acres of land, which includes a steel framed building representing 15,500 sq. ft. of grow area, and a planned expansion of up to 420,000 sq. ft.

Jag Bal, President and CEO of Umbral, stated “As Umbral makes this payment, it marks another stage for PhyeinMed to continue to move forward on its path to being a licensed grower in Canada. The whole team is working hard to ensure we can commence our build-out quickly once we take possession of the property”.

UMBRAL ANNOUNCES NON-BROKERED UNIT PRIVATE PLACEMENT

Vancouver, B.C., July 14, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) announcesthat non-brokered private placement consisting of up to 34,000,000 units (the “Units”) at a purchase price of $0.06 per Unit to raise gross proceeds of up to $2,040,000 (the “Private Placement”).Each unit will consist of one common share in the capital of the Company and one share purchase warrant (a “Warrant”).Each full warrant will entitle the holder to purchase one additional common share in the capital of the Company for a period of 2 years, at a purchase price of $0.10 per Share.

The Company may pay a finder’s fee in connection with the Private Placement within the amount permitted by the policies of the Exchange.Certain directors, officers and insiders of the Company may participate in the Private Placement.The Private Placement is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange.All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

The Warrants are subject to an accelerated expiry if, anytime following the expiration of the four-month hold period, the Shares trade at a price equal to or greater than $0.20 on the CSE such other market as the Shares may trade from time to time, for ten (10) consecutive trading days, in which event the Subscriber may, at the Issuer’s election, be given notice that the Warrants of the Issuer will expire 30 days following the date of such notice.The Warrants may be exercised by the Holder during the 30 day period between the notice and the expiration of the Warrants.

The net proceeds from the Private Placement will be used by the Company to pay the balance of purchase price for Falkland, BC property, completion of phase 1 of the build-out prior to an award of a license to cultivate, fund a work program for Letourneur Property and for general working capital.

START UP MATERIALS SECURED FOR PRODUCTION

Vancouver, B.C., July 20, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) on behalf of the management of PhyeinMed Inc. (“PhyeinMed”), a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations), announces that it has signed an agreement with CanGenX BioTech Inc. (CanGenX) to undertake plant tissue culture as its production basis.

CanGenX provides advanced production technologies to the legal medical cannabis industry. PhyeinMed expects that applied science can be used to gain a competitive edge in this newly regulated marketplace. This is done using ‘tissue culture micro-propagation’, which can take one plant and multiply it into thousands within a few months. allowing PhyeinMed to take its best performing plants and replicate them to fill their entire production system. The intended result is to create genetically uniform, robust, and disease-free starting plant material, and thereby eliminating traditional propagating methods which are subject to genetic variability, reduced germination and survival rates, and can contain disease. CanGenX facilitates the supply of high volume tissue culture starter plants in house with the purpose of permitting PhyeinMed to produce the safest cannabis possible.

Debra Senger, CEO of PhyeinMed states “we are excited to move forward with CanGenX as we expect it to deliver us many benefits including uniformity of crop, quicker propagation and a savings of cost and time in production. In this new competitive market, we are aiming to be a quality producer while focusing on optimizing returns in our operations.”

In addition, CanGenX will consult on the set up a propagation lab facility as well as supplying proprietary strain-specific media to PhyeinMed on demand.

UMBRAL ENERGY CORP. | ANNUAL GENERAL MEETING

Vancouver, B.C., July 26, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) is pleased to advise, at the Umbral Energy Corp’s annual general meeting held on July 7, 2017, shareholders of the company approved all the items, including:

  • Election of Jagdip Bal, Brad Culver & Clint Sharples as directors;
  • Appointment of Morgan & Co LLP as auditors.

UMBRAL’S SUBSIDIARY PHYEINMED JOINS THE CANOPY GROW FAMILY

Vancouver, B.C., August 8, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) is pleased to announce that its 75% owned subsidiary, PhyeinMed Inc. (“PhyeinMed”) a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) has signed an agreement with Canopy Growth Corporation (TSX:WEED) (“Canopy Growth”) to supply cannabis products via the CraftGrow line on Tweed Main Street’s online store.

Pending receiving a licence to cultivate and sell cannabis products from Health Canada, PhyeinMed stands to substantially accelerate its speed to market through joining the CraftGrow program and leveraging their marketing and distribution network. Canopy is widely recognized as leading the way in the Canadian cannabis market, and has a global reputation for providing top quality products and partnering with other top producers. This partnership also allows PhyeinMed to significantly reduce market acquisition costs for infrastructure, while driving early revenue through Tweed Main Street’s online store.

Mark Zekulin, President of Canopy Growth, has previously commented regarding the CraftGrow opportunity, “Our approach with CraftGrow and Tweed Main Street is to establish a diverse online marketplace for legal medical cannabis products. People can seamlessly access Canada's leading cannabis brands with one medical document rather than being tied to a single producer. For new producers, having access to the largest group of registered patients in the country can go a long way towards building brand awareness. And for us, it's an opportunity to position ourselves as the online source of cannabis in Canada, while bringing more product variety and reliability to our customers."

PhyeinMed is pleased by recent developments and conversations confirming that Health Canada has streamlined licensing in order to move applicants through the process more effectively.These efforts have created a more open discussion between PhyeinMed and the Offices of Medical Cannabis reducing the uncertainty as to the administrative steps required to obtain a production license.

“Our collaborative agreement with Canopy Growth is a major milestone for us.” states PhyeinMed CEO, Debra Senger,“As a late stage applicant we recognize the need to optimize our exposure and brand awareness, and by utilizing Canopy Growth's Tweed Main Street it gives us access to a large consumer base in an expanding medical cannabis market. We intend to offer high quality products which we believe will be popular with the substantial customer base Canopy has established. This agreement gives us a true partner in the industry and will expose us to industry leading expertise, knowledge and best practices. These learnings will be very valuable to PhyeinMed as we progress through the final steps of licensing.We are very pleased to be working with such a global leader in the cannabis space.”

Incentive Stock Option Grant

Vancouver, B.C., August 16, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) announces, that it has granted a total of 2,000,000 incentive stock options to directors/officers/employees and/or consultants under the Company’s Stock Option Plan.  The options are exercisable at $0.10 per share and will expire August 16, 2022.  Following this grant of options, the Company has 3,500,000 stock options outstanding.

These incentive stock options are being granted to Debra Senger as set out in the Share Purchase Agreement announced by News Release July 5, 2017.  Debra is the President and CEO of PhyeinMed Inc., a Health Canada la‍‍‍te stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations)